Edwards Lifesciences Raises FY2026 Adj EPS Guidance from $2.90-$3.05 to $2.95-$3.05 vs $2.93 Est; Widens FY2026 Sales Guidance from $6.553B-$6.674B to $6.500B-$6.900B vs $6.679B Est

Benzinga Newsdesk www.benzinga.com Positive 85.5%

Neg 0% Neu 0% Pos 85.5%

Edwards Lifesciences (NYSE:EW) raises FY2026 Adj EPS guidance from $2.90-$3.05 to $2.95-$3.05 vs $2.93 analyst estimate. Widens FY2026 sales outlook from $6.553 billion-$6.674 billion to $6.500 billion-$6.900 billion vs $6.679 billion estimate.